Home
>
Drugs
>
Autosomal recessive cerebral arteriopathy and arteriosclerosis with subcortical infarcts and leukoencephalopathy
Autosomal recessive cerebral arteriopathy and arteriosclerosis with subcortical infarcts and leukoencephalopathy
CARASIL is the abbreviation of cerebral autosomal recessive arteriopathy/arteriosclorosis with subcortical infarcts and leukoencephalopathy (CARASIL), also known as young-onset Binswanger-like leukoencephalopathy with baldness and low back pain (Fukutake, 1998). Fukutake (1985) reported a family of three young brothers with neurological symptoms and imaging features similar to Binswanger disease. He reviewed four cases published in Japan in 1965, which lacked risk factors for cerebrovascular disease and all had baldness and low back pain, pointing out that it might be an autosomal recessive syndrome.
-
Site of disease:
Skull head waist -
Infectious :
Not contagious -
Frequent population:
young people -
Related symptoms:
Lower limb weakness lysosomal enzyme deficiency progressive dementia memory impairment super masculinity -
Concurrent disease:
Related Drugs
Brain Capsules
Manufacturer:
Jiangxi Guangxin Pharmaceutical Co., Ltd.
Fenofibrate
Indication: Adults with hypercholesterolemia and/or hypertriglyceridemia who are unsatisfactory with dietary therapy.
Manufacturer:
Nexchem Pharmaceutical Co., Ltd.
Simvastatin
Indication: 1. When dietary therapy and other non-drug treatments for hypercholesterolemia are ineffective, simvastatin can be used to reduce total cholesterol and low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Simvastatin can also increase high-density lipoprotein cholesterol and thus reduce the ratio of low-density lipoprotein cholesterol/high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol. In patients with combined hypercholesterolemia and hypertriglyceridemia, when hypercholesterolemia is the main abnormality, it can reduce elevated cholesterol levels; 2. For patients with coronary heart disease, simvastatin is suitable for: reducing the risk of death; reducing the risk of death from coronary heart disease and non-fatal myocardial infarction; reducing myocardial revascularization surgery (coronary artery bypass grafting and percutaneous balloon coronary angioplasty); delaying the progression of atherosclerosis, including the occurrence of new lesions and total blockage.
Related Ingredients
-
Propachlor list
1918-16-7 -
Fenofibrate list
49562-28-9 -
Simvastatin list
79902-63-9